Hot Products

VCAP

Cat.No.: CSC-C8204L

Species: Homo sapiens, human

Source: Prostate metastasis

Morphology: epithelial

Culture Properties: adherent

  • Specification
  • Background
  • Scientific Data
  • Q & A
  • Customer Review
Cat.No.
CSC-C8204L
Description
This cell line was established from prostate cancer tissue harvested from a metastatic lesion to a lumbar vertebral body of a patient with hormone refractory prostate cancer. The cells are reported to express large quantities of prostate specific antigen (PSA). This cell line also expresses prostatic acid phosphatase (PAP), cytokeratin-18 and the androgen receptor, and is androgen sensitive in vitro and in vivo. This cell line offers a cell-based model system of human prostate cancer. The cells are tumourigenic in SCID mice.
Species
Homo sapiens, human
Tissue of Origin
Prostate metastasis
Source
Prostate metastasis
Recommended Medium
Culture Properties
adherent
Morphology
epithelial
STR DNA Profile
Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 11,12
D16S539: 9
D5S818: 12
D7S820: 9,12
THO1: 9.3
TPOX: 8,11
vWA: 18,19
Application
It has been shown that VCaP prostate cancer cells produce the mouse xenotropic retrovirus Bxv-1, which was likely acquired by the cells during their xenotransplantation in mice.
Disease
Prostate carcinoma
Quality Control
Tests for mycoplasma, bacteria and fungi were negative
Storage and Shipping
liquid nitrogen vapor phase
Citation Guidance
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the PubMed ID of your paper to get a coupon.

VCaP (Vertebral Cancer of the Prostate) cell line is a well-characterized in vitro model, derived from a vertebral metastasis of castration-resistant prostate cancer (CRPC). First established in 1997, this cell line has been extensively studied and possesses some notable characteristics that make it a valuable tool for prostate cancer research.

VCaP is an epithelial adherent cell line with moderate growth kinetics and a doubling time of 48-72 hours under standard culture conditions. The VCaP cell line shows overexpression of both wild-type androgen receptor (AR) and estrogen receptor alpha (ERα). This unique property makes VCaP an attractive model to study both androgen and estrogen signaling in prostate cancer. In addition to the AR and ERα expression, the VCaP cells also harbor the TMPRSS2-ERG gene fusion, which is present in approximately 50% of clinical prostate cancer cases.

Originating from a metastatic lesion in the bone, VCaP is particularly useful for studying the mechanisms underlying CRPC development and bone metastasis. The cells have been employed to study AR signaling dynamics, therapeutic resistance mechanisms, and tumor-microenvironment interactions. VCaP cells can also form tumors in xenograft models.

Growth characteristics and morphology of VCaP cell lines with different sensitivity to testosterone (A-B) and drug resistances (C-E).

Fig. 1. Growth characteristics and morphology of VCaP cell lines with different sensitivity to testosterone (A-B) and drug resistances (C-E) (Nätkin R, Paloneva M I, et al., 2025).

Bulk mRNA-Sequencing Data of the Estrogen and Androgen Responses in the Human Prostate Cancer Cell Line VCaP

Estrogen signaling in prostate cancer (PCa) is under-investigated compared to well-established androgen dependence. VCaP cells, expressing wild-type AR and ERα, are ideal for investigating these hormonal interactions. Lafront et al. generated a transcriptomic atlas of androgen and/or estrogen-dependent transcriptional changes in VCaP cells using bulk mRNA-seq.

VCaP cells were treated with androgens and/or estrogens for 24 h, mRNA purified, sequenced, and aligned to the human transcriptome. Transcriptomic changes were analyzed after quantification. The raw data were submitted to the Gene Expression Omnibus (GEO) repository and can be found using the GSE256370 reference number. The dataset contains 12 samples (exact number of four treatment groups: control, R1881 [synthetic androgen], estradiol and estradiol + R1881, with three replicates per group) and, here, were used to test the downregulated transcriptional response upon stimulation by androgen and estrogen with the GSEA tool (Fig. 1).

Androgens and estrogens significantly downregulate both similar and distinct biological pathways in the VCaP cell line.

Fig. 1. Androgens and estrogens significantly downregulate both similar and distinct biological pathways in the VCaP cell line (Lafront G, Germain L, et al., 2024).

Androgen- and PKA Signaling-Induced Changes in the Proteomic Profile of VCaP Cells and Identification of Differentially Expressed Proteins

Androgen signaling is crucial in prostate cancer, but resistance leads to CRPC, where PKA may bypass androgen dependence. The key proteins involved remain unknown. You’s team aims to identify proteins regulated by androgen and PKA signaling in VCaP prostate cancer cells, uncovering potential molecular mechanisms behind CRPC progression and therapeutic targets.

VCaP cells were treated with androgen or forskolin (activator of PKA) then subjected to proteomic analysis to quantify the differentially expressed proteins. In total, 113 protein spots that have different expression between the control and DHT or FSK were detected. Among these, eight spots display significant changes in density (> 1.5-fold changes in expression, p < 0.05). These eight differentially expressed proteins (Fig. 2) were significantly increased in response to DHT or FSK in three repeat experiments (Fig. 3). The proteins were subsequently identified by MS analyses. Three proteins were found to be altered in VCaP cells in response to DHT: LDHB, TUFM and HNRNPH3. Five proteins were specifically increased in response to FSK: OXCT1, ACPP, IMPDH2, CCT2 and HNRNPK. To further understand the functional implication of these proteins, they performed a Gene Ontology (GO) analysis on the cellular location and biological function of the proteins. The GO analysis revealed that all the identified proteins are involved in the metabolic process. Notably, metabolic reprogramming has been linked to AR signaling re/activation and antagonism that drives the progression of CRPC.

2DE analysis and identification of protein spots showing significant changes in expression between the control group and DHT-or FSK-treated groups.

Fig. 2. 2DE analysis and identification of protein spots showing significant changes in expression between the control group and DHT-or FSK-treated groups (You H-J, You B-C, et al., 2021).

Comparative expression levels of the identified protein spots.

Fig. 3. Comparative expression levels of the identified protein spots (You H-J, You B-C, et al., 2021).
What is the difference between TEM and scanning electron microscopy (SEM)?

The main difference between TEM and SEM lies in the imaging technique. While TEM passes electrons through a thin specimen to create an image, SEM scans a focused beam of electrons across the surface of a specimen to generate a 3D image. TEM provides higher resolution for internal structure analysis, while SEM is better suited for surface imaging.

Ask a Question

Average Rating: 5.0    |    1 Scientist has reviewed this product

Reliable

As a cancer biologist, the tumor cells I purchase from Creative Bioarray maintain their genetic and phenotypic characteristics, allowing me to study key pathways and mechanisms associated with tumors.

13 Apr 2023


Ease of use

After sales services

Value for money


Write your own review

  • You May Also Need

For research use only. Not for any other purpose.